AKT1 and Alzheimer disease: These findings indicate that both treatments activated PI3K–AKT, AMPK, and JAK2/3 signaling pathways and inhibited GSK-3β, which may contribute to neuronal survival, metabolic regulation, and immune homeostasis in AD pathology.